Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

76 results about "Pyrimidifen" patented technology

Pyrimidifen is a pyrimidinamine insecticide, a pyrimidinamine acaricide and an aminopyrimidine. It has a role as a mitochondrial NADH : ubiquinone reductase inhibitor. Ontology Summary from ChEBI

Solid dispersion of myeloid kinome inhibitors and pharmaceutical composition comprising the same

A solid dispersion of 5-chloro-N-(3-cyclopropyl-5-{[(3R,5S)-dimethylpiperazin-1-yl]methyl}phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of 5-chloro-N-(3-cyclopropyl-5-{[(3R,5S)-dimethylpiperazin-1-yl]methyl}phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine and uses thereof are provided herein.
Owner:HANMI PHARM CO LTD

Preparation and application of trifluoroethyl thiophenylpyrimidinamine derivative

The invention relates to preparation and application of a trifluoroethyl thiophenylpyrimidinamine derivative. Specifically, the invention relates to a compound as shown in a formula (I), or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt thereof, and application of the compound in preparation of insecticides for pest control. The compound can achieve a better pest control effect at a lower dosage, especially for pests such as tetranychidae, microcosaridae, acaridae, tarsonidae, aleuridae and root-knot nematode, and can be used for controlling pests such as tetranychidae, microcosaridae, gall mite, tarsonidae, aleuridae and the like. # imgabs0 #
Owner:ZHEJIANG HISUN CHEM CO LTD

Pyrrolo [2, 3-d] pyrimidine-4-amine derivative and application thereof in medicine

The invention relates to a pyrrolo [2, 3-d] pyrimidine-4-amine derivative and application thereof in medicine, in particular to a compound shown in a formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, pharmaceutically acceptable salt or eutectic of the compound, and application of the compound in preparation of medicines for treating sGC-related diseases.
Owner:HAISCO PHARMACEUTICAL GROUP CO LTD

Crystal form of bipyrimidine compound, preparation method therefor and use thereof

The present invention relates to a crystal form of a bipyrimidine compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a crystal form I of 4'-cyclopropyl-5,6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)bicyclic[2.2.2]oct-1-yl)methyl)-[2,5'-bipyrimidine]-4-amine, and the X-ray powder diffraction pattern of the crystal form I comprises characteristic peaks at diffraction angles (2θ) of 6.378±0.2°, 9.521±0.2°, 15.721±0.2°, 16.379±0.2°, 16.981±0.2°, 17.560±0.2°, 19.080±0.2°, and 22.200±0.2°. The crystal form I has high stability, high solubility, high plasma concentration, high bioavailability, and excellent pharmacological action, and is therefore suitable for pharmaceutical preparations.
Owner:JIANGSU YAHONG MEDITECH CO LTD +1

A pyrimidineamine NUAK inhibitor, its preparation method and uses

The present application provides a pyrimidineamine compound, characterized in that the pyrimidineamine compound is a compound represented by Formula I, or its stereoisomer, tautomer, isotope derivative, hydrate, solvate, prodrug, and pharmaceutically acceptable salt. The pyrimidineamine compound described in the present application has excellent NUAK1 / NUAK2 kinase inhibitory activity and can be used for preventing or treating the following diseases by inhibiting NUAK1 / NUAK2: neuropsychiatric diseases, metabolic diseases, tumors, visceral fibrosis diseases, and skin fibrosis diseases. #imgabs0#
Owner:TECHNODERMA MEDICINES

Ceramic coating for metal door and preparation method thereof

The invention discloses a ceramic coating for a metal door and a preparation method of the ceramic coating, and relates to the technical field of coatings. The prepared ceramic coating is prepared from sodium silicate, methyltrimethoxysilane, modified polyacrylate emulsion, modified silicon dioxide, glass powder, sodium fluosilicate, a dispersing agent, a flatting agent and pure water. The modified polyacrylate emulsion is obtained by polymerizing a phosphorus-containing monomer and a vinyl monomer to generate polyacrylate, carrying out sulfonyl chlorination on the polyacrylate, reacting with 5-chloromethyl-2-pyrimidinamine, and emulsifying; the preparation method comprises the following steps: polymerizing aniline on the surface of pretreated silicon dioxide, reacting with 1-benzothiophene-5-carbonyl chloride, salinizing with diphenyl iodide trifluoromethanesulfonate and copper acetate, and reacting with bis (2-ethynylphenyl) sulfane to obtain the silicon dioxide. The prepared ceramic coating has good corrosion resistance, antibacterial property and ageing resistance, and the performance of the metal door is greatly improved.
Owner:SHENZHEN CAIMEN INTELLIGENT TECH CO LTD

Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Disclosed herein are tricyclic compounds, including pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4′,5′:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
Owner:VANDERBILT UNIV

Crystalline form of bipyrimidine compounds, method of preparation thereof, and use thereof

The present invention relates to the crystalline form of bipyrimidine compounds, as well as methods for preparing the same and their use. In particular, the present invention relates to crystalline form I of 4'-cyclopropyl-5,6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazole-2-yl)bicyclo[2.2.2]octan-1-yl)methyl)-[2,5'-bipyrimidine]-4-amine, wherein the X-ray powder diffraction pattern of crystalline form I includes characteristic peaks at diffraction angles (2θ) of 6.378±0.2°, 9.521±0.2°, 15.721±0.2°, 16.379±0.2°, 16.981±0.2°, 17.560±0.2°, 19.080±0.2° and 22.200±0.2°. Crystal form I possesses high stability, high solubility, high plasma concentration, high bioavailability, and excellent pharmacological activity, making it suitable for pharmaceutical preparations.
Owner:JIANGSU YAHONG MEDITECH CO LTD +1

Synthesis method of 7H-pyrrolo [2, 3-d] pyrimidine-4-amine

PendingCN119638703Aguaranteed yieldImprove the quality of purityOrganic chemistryFormamidine acetateOrganic base
The invention relates to a synthesis method of 7H-pyrrolo [2, 3-d] pyrimidine-4-amine, and belongs to the technical field of synthesis of drug intermediates. In order to solve the problems of easy generation of metal residues and low yield in the prior art, the invention provides a synthetic method of 7H-pyrrolo [2, 3-d] pyrimidine-4-amine, which comprises the following steps: in the presence of alkali, reacting aziridine with malononitrile to obtain a compound shown as a formula III; under the action of organic alkali and trichloroisocyanuric acid, the compound shown in the formula III is subjected to oxidative dehydrogenation reaction to be converted into 2-amino-3-cyano-1H-pyrrole; the 2-amino-3-cyano-1H-pyrrole and formamidine acetate are subjected to a reaction, and the 7H-pyrrolo [2, 3-d] pyrimidine-4-amine is obtained. According to the method, the problem of metal residues caused by the adoption of a noble metal catalyst can be effectively avoided, the product yield is better guaranteed, the high-purity quality effect is achieved, and the purity of an intermediate product in each step can reach 99% or above.
Owner:TAIZHOU VOCATIONAL & TECHN COLLEGE

Pyrido[2,3-d]pyrimidin-4-amines as SOS1 inhibitors

The present invention relates to a pyrido[2,3-d]pyrimidine-4-amine compound of general formula (I): wherein R 1 、R 2 、R 3 , A, x and y are as defined herein; methods for preparing the compounds; intermediate compounds used to prepare the compounds; pharmaceutical compositions and combinations comprising the compounds; and the use of the compounds as a single agent or in combination with other active ingredients for the preparation of pharmaceutical compositions for treating or preventing diseases, particularly hyperproliferative diseases.
Owner:BAYER AG

Preparation method of pyrrolopyrimidine-4-amine derivative

The invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method of a pyrrolopyrimidine-4-amine derivative, which selects methanol, ammonium formate and formic acid as a reaction system to carry out directional reaction, avoids the use of high-pressure hydrogen and a high-pressure kettle, avoids the safety risk caused by high-pressure operation, and improves the yield of the pyrrolopyrimidine-4-amine derivative. And the alcoholic solution solves the problems of low solubility and obvious amplification effect of a starting material when water is used as a solvent in the prior art, and realizes homogeneous reaction. By adopting the fixed bed reaction unit, the problem of pipeline blockage caused by sublimation of ammonium formate is solved, the potential safety hazard in large-scale production is eliminated, the fixed bed reaction unit is used for continuous catalytic reaction to replace the traditional staged reaction, the production period is remarkably shortened, the production efficiency is improved, and the method is suitable for large-scale industrial production.
Owner:SHANDONG XUANSHUO PHARM TECH CO LTD

Pyridin[3,2-d]pyrimidin-2-amine derivative, preparation method therefor, and use thereof

A pyridin[3,2-d]pyrimidin-2-amine derivative, a preparation method therefor, and a use thereof. The pyridin[3,2-d]pyrimidin-2-amine derivative can be used as a TLR7 / 8 dual agonist, and is used for treating diseases related to TLR activity, such as diseases caused by virus (such as HBV and HIV) infection, tumors, and inflammatory diseases. In particular, the provided pyridin[3,2-d]pyrimidin-2-amine derivative has better physicochemical properties, druggability, cardiac safety and oral bioavailability, and has very good research and application value in the field of medicine.
Owner:BEIJING SYNTHETIC VACCINE BIOSCIENCES CO LTD

Preparation method of 4-chloro-5H-pyrrolo [3, 2-D] pyrimidine-2-amine

The invention relates to a preparation method of 4-chloro-5H-pyrrolo [3, 2-D] pyrimidine-2-amine, which comprises the following steps: step 1, synthesizing a compound B from a compound A; 2, synthesizing a compound C from the compound B; 3, synthesizing a compound D from the compound C; wherein the structures of the compound A, the compound B, the compound C and the compound D are respectively as follows: # imgabs0 #. Compared with the prior art, the preparation method disclosed by the invention has the advantages that the process is simple, only three-step reaction is needed, and complicated post-treatment is not needed; the cost is controllable, raw materials are easy to obtain, reagents are cheap, and the prepared compound is a key intermediate of kinase inhibitor drugs, has important application value in research and development of anti-cancer and anti-inflammatory drugs and has high potential economic benefits; the method has no harsh reaction conditions, is simple to operate and is suitable for large-scale production.
Owner:SHANGHAI UNIV

Ceramic coating for metal doors and method for its preparation

The application discloses a ceramic paint for metal doors and a preparation method thereof, and relates to the technical field of paints. The ceramic paint prepared by the application contains sodium silicate, methyltrimethoxysilane, modified polyacrylate emulsion, modified silicon dioxide, glass powder, sodium fluorosilicate, dispersant, leveling agent and pure water. The modified polyacrylate emulsion is obtained by polymerizing phosphorus-containing monomers and vinyl monomers to generate polyacrylate, reacting the polyacrylate with 5-chloromethyl-2-pyrimidine amine after sulfonyl chlorination, and then emulsifying. The silicon dioxide is obtained by polymerizing aniline on the surface of pretreated silicon dioxide, reacting with 1-benzothiophene-5-carbonyl chloride, then salifying with diphenyl iodonium triflate and copper acetate, and then reacting with bis(2-ethynylphenyl) sulfane. The ceramic paint prepared by the application has good corrosion resistance, antibacterial property and anti-aging property, and greatly improves the performance of the metal door.
Owner:SHENZHEN CAIMEN INTELLIGENT TECH CO LTD

A kind of preparation method of mesosulfuron

The invention discloses a method for preparing mesosulfuron, wherein pyrimidine amine and a phosgene compound are reacted to obtain isocyanate, and then the isocyanate is condensed with 5-methylsulfonylaminomethyl-2-methoxycarbonylbenzenesulfonamide to obtain mesosulfuron. The method of the invention has high yield, high purity of the obtained product, and few by-products are generated during the preparation process and are easy to recover.
Owner:JIANGSU REPONT PESTICIDE FACTORY

Porous coordination polymers with interpenetrating frameworks, methods of preparation and applications in ethane / ethylene separations at high temperatures

The present application relates to a kind of porous coordination polymers with interpenetrating framework, preparation method and application in ethane / ethylene high temperature separation, belong to coordination chemistry material technical field.Porous coordination polymers are Cu-based coordination polymers, its chemical formula is [Cu2 (BDC) 2L2] n (solvent) x , belong to C2 / c space group, L2 is 4,6-di (1H-1,2,4-triazole-1-yl) pyrimidine-2-amine, NH2 Group is again with adjacent framework forms single hydrogen bond;It is obtained by adding regulating ligand during solvothermal reaction of ligand and metal salt.The present application proposes a new method to regulate temperature-dependent dynamic characteristics in hydrogen-bonded interpenetrating framework, with the weakening of hydrogen bond, porous coordination polymers with one-dimensional narrow-neck channel exhibit promising structural response to ethane / ethylene at high temperature, so that it shows significant ability to directly obtain polymerization grade ethylene.
Owner:NANJING TECH UNIV

A preparation method of ibrutinib

The present invention belongs to the technical field of drug synthesis, and in particular to a method for preparing ibrutinib. The present invention uses 3-bromo-1H-pyrazolo[3,4-D]pyrimidine-4-amine as a raw material, and reacts with 4-phenoxyphenylboronic acid under amine catalysis to obtain 4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine; 4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine is reacted with 1-[(S)-3-hydroxy-1-piperidinyl]-2-propylene-1-one under the catalysis of phosphine oxide to obtain ibrutinib through Mitsunobu reaction. This process uses amine catalysts instead of precious metal palladium to catalyze the Suzuki coupling reaction, which solves the problems of low yield and expensive catalysts in traditional reactions of this type. It uses phosphine oxide as a catalyst to catalyze the Mitsunobu reaction, avoiding the use of equivalent triphenylphosphine in the Mitsunobu reaction, and solves the harsh conditions of the reaction itself that require the acidity of the nucleophilic reagent. The process is simple to operate, and the target product obtained is of high purity, which is suitable for industrial production.
Owner:SHANDONG NEW TIME PHARMA CO LTD

Crystal form of bipyrimidine compound and preparation method and application thereof

The invention relates to a crystal form of a bipyrimidine compound as well as a preparation method and application thereof. In particular, the present invention relates to a crystalline form I of 4 '-cyclopropyl-5, 6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl) bicyclo [2.2. 2] oct-1-yl) methyl)-[2, 5 '-bipyrimidinyl]-4-amine, a crystalline form II of 4'-cyclopropyl-5, 6 '-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl) bicyclo [2.2. 2] oct-1-yl) methyl)-[2 An X-ray powder diffraction pattern of the compound comprises characteristic peaks at diffraction angles (2 theta) of 6.378 + / -0.2 degrees, 9.521 + / -0.2 degrees, 15.721 + / -0.2 degrees, 16.379 + / -0.2 degrees, 16.981 + / -0.2 degrees, 17.560 + / -0.2 degrees, 19.080 + / -0.2 degrees and 22.200 + / -0.2 degrees. The crystal form I is high in stability, high in solubility, high in blood concentration, high in bioavailability and excellent in pharmacological action, so that the crystal form I is suitable for pharmaceutical preparations.
Owner:JIANGSU YAHONG MEDITECH CO LTD +1

An environmentally friendly polyacrylate lithium battery adhesive tape

The invention discloses an environmentally friendly polyacrylate lithium battery adhesive tape, and the preparation method comprises the following steps: (1) butyl acrylate, N-(trimethylsilyl)-2-(trimethylsilyl)-4-pyrimidinamine, amino-modified emulsion, dipropylene glycol diacrylate, methyl methacrylate, ammonium lauryl alcohol ether sulfate, EG emulsifier and ethyl acetate are mixed and stirred uniformly to obtain a mixture A; (2) a portion of the mixture A is mixed with an aqueous solution of ammonium persulfate and ammonium bicarbonate, the mixture is kept at a constant temperature in a water bath, and then the remaining mixture A is added, and the mixture is kept warm and stirred, and after the stirring is completed, the mixture is cooled to 70±5°C and kept warm for more than 1h, and then air-cooled to room temperature to obtain a mixture B; (3) the mixture B is coated on a PET film, dried, and then transferred to an oven at 60±2°C for placement, and then air-cooled to room temperature to obtain the lithium battery adhesive tape. The lithium battery adhesive tape prepared by the method of the present invention has good adhesive retention and high temperature resistance, and improves the safety of the adhesive tape.
Owner:HUNAN YOUDUO NEW MATERIAL TECH CO LTD

A pyrimidineamine-based NUAK inhibitor, its preparation method and uses

The present application provides a pyrimidineamine compound, which is characterized in that the pyrimidineamine compound is a compound represented by Formula I, or its stereoisomer, tautomer, isotope derivative, hydrate, solvate, prodrug and pharmaceutically acceptable salt. The pyrimidineamine compound described in the present application has excellent NUAK1 / NUAK2 kinase inhibitory activity and can be used for preventing or treating the following diseases by inhibiting NUAK1 or NUAK2: neuropsychiatric diseases, metabolic diseases, tumors, visceral fibrosis diseases, and skin fibrosis diseases.
Owner:TECHNODERMA MEDICINES

Pyrimidinamine NUAK inhibitor as well as preparation method therefor and use thereof

PCT designated stage expiredWO2025011444A1Organic active ingredientsNervous disorderFibrosisDepressant
Provided in the present application are pyrimidinamine compounds, characterized in that the pyrimidinamine compounds are compounds represented by formula I, or stereoisomers, tautomers, isotope derivatives, hydrates, solvates, prodrugs and pharmaceutically acceptable salts thereof. The pyrimidinamine compounds of the present application have excellent NUAK1 / NUAK2 kinase inhibitory activity, and thus can be used for preventing or treating the following diseases by means of inhibiting NUAK1 or NUAK2: neuropsychiatric diseases, metabolic diseases, tumors, visceral fibrosis diseases, and skin fibrosis diseases.
Owner:TECHNODERMA MEDICINES

METHOD FOR PRODUCING 7H-PYRROLO [2, 3-d] PYRIMIDIN-4-AMINE DERIVATIVE

Provided is a method for producing a compound represented by formula (I) which is suitable for mass synthesis as an API. According to one embodiment of the present invention, provided is a method for producing a compound represented by formula (I) or a salt thereof, comprising a step for forming the compound represented by formula (I) or a salt thereof by deprotecting a protecting group represented by formula (II) R1 under alkaline conditions. # imgabs0 #
Owner:TAIHO PHARMA CO LTD

Pyrimidinamine NUAK inhibitor as well as preparation method therefor and use thereof

PCT designated stage expiredWO2025011446A1Organic active ingredientsNervous disorderFibrosisDepressant
Provided in the present application are pyrimidinamine compounds, characterized in that the pyrimidinamine compounds are compounds represented by formula I, or stereoisomers, tautomers, isotope derivatives, hydrates, solvates, prodrugs and pharmaceutically acceptable salts thereof. The pyrimidinamine compounds of the present application have excellent NUAK1 / NUAK2 kinase inhibitory activity, and thus can be used for preventing or treating the following diseases by means of inhibiting NUAK1 / NUAK2: neuropsychiatric diseases, metabolic diseases, tumors, visceral fibrosis diseases and skin fibrosis diseases.
Owner:TECHNODERMA MEDICINES

Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors

The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Owner:INCYTE CORP

Pyrimidinamine NUAK inhibitor, and preparation method therefor and use thereof

PCT designated stage expiredWO2025011447A1Organic active ingredientsNervous disorderFibrosisDepressant
Provided in the present application is a pyrimidinamine compound, which is characterized in that the pyrimidinamine compound is a compound as shown in formula I, or a stereoisomer, tautomer, isotopic derivative, hydrate, solvate, prodrug and pharmaceutically acceptable salt thereof. The pyrimidinamine compound of the present application has an excellent NUAK1 / NUAK2 kinase inhibitory activity, and can be used for preventing or treating the following diseases by inhibiting NUAK1 / NUAK2: neuropsychiatric diseases, metabolic diseases, tumors, visceral fibrotic diseases and skin fibrotic diseases.
Owner:TECHNODERMA MEDICINES

6-arylquinazolin-4-amine and 6-arylpyridopyrimidin-4-amine derivatives, and use thereof as PI3kδ covalent inhibitors

Disclosed in the present invention are 6-arylquinazolin-4-amine and 6-arylpyridopyrimidin-4-amine derivatives, and the use thereof as PI3Kδ covalent inhibitors. Said derivatives disclosed by the present invention are compounds capable of being used as PI3Kδ inhibitors. PI3Kδ kinase activity and PI3K selectivity tests verify that the compounds disclosed in the present invention exhibit an obvious inhibition effect on PI3Kδ kinase activity and have obvious selectivity on the activity of PI3Kδ. In-vitro cell anti-proliferative activity tests by means of using various blood tumor cell lines exhibit that the compounds disclosed in the present invention have different inhibition effects on various blood tumor cells.
Owner:XI AN JIAOTONG UNIV

Sterilization defoaming agent for foam drainage and preparation method thereof

The invention belongs to the technical field of oil and gas development, and particularly relates to a sterilization defoaming agent for foam drainage and a preparation method thereof. The cleaning agent is prepared from the following components: alkynediol polyether modified silicone oil, polyoxyethylene polyoxypropylene pentaerythritol ether, modified nano silicon dioxide, an emulsifier, a mutual solvent, a benzyl quaternary ammonium salt disinfectant, a pyrilamine bactericide and water. The preparation method comprises the following steps: heating and stirring the alkynediol polyether modified silicone oil, adding the modified nano silicon dioxide, stirring, cooling, reducing the stirring speed, adding the polyoxyethylene polyoxypropylene pentaerythritol ether, and continuously stirring to obtain an intermediate product A; adding water into another reaction kettle, heating and stirring, then adding an emulsifier, a mutual solvent, a benzyl quaternary ammonium salt disinfectant and a pyrilamine bactericide, stirring to obtain an intermediate product B, and then heating; and adding the intermediate product A into the intermediate product B, and stirring. The sterilizing and defoaming agent for foam drainage has multiple functions of sterilizing and defoaming, and realizes multiple effects by one agent.
Owner:CHENGDU XINMING CHEM CO LTD

Regioselective Synthesis of Imidazolo[1,2-a]pyrimidines

The present disclosure provides a method for regioselectively synthesizing an imidazo[1,2-a]pyrimidine compound of formula (XXa) or (XXb), #imgabs0# the method comprising the step of coupling a first compound of formula XX-P1a or XX-P1b with a second compound of formula XX-P2. #imgabs1# The cyclization reaction between β-ethoxyacrylamide and phosphorylated aminoimidazole to generate imidazo[1,2-a]pyrimidine-amine relies on the directing effect from the intra- and extra-cyclic phosphorylated aminoimidazole. The reaction generates 2-amino or 4-amino structural isomers of imidazo[1,2-a]pyrimidine with good yields and a regioselectivity range of 90:10-99:1. The reaction can be used to synthesize a variety of tracer molecules used in neurological disease research, such as those in which R 3 and R 4 Together with the imidazole ring atom to which they are bonded, a benzene ring is formed, and the product is a substituted benzimidazolopyrimidine. The reaction can be summarized as forming an imidazo[1,2-a]pyrimidine substituted at its 2- and 4-positions by an alkoxy or thioalkyl group.
Owner:F HOFFMANN LA ROCHE & CO AG

Method for detecting related impurities of imatinib mesylate intermediate

The invention belongs to the technical field of medicine detection, and particularly relates to a method for detecting related impurities of an imatinib mesylate intermediate. In particular to a method for detecting related substances in N-(2-methyl-5-nitrophenyl)-4-(pyridine-3-yl) pyrimidine-2-amine. The related substances in N-(2-methyl-5-nitrophenyl)-4-(pyridine-3-yl) pyrimidine-2-amine are detected by high performance liquid chromatography, and the content of each impurity in N-(2-methyl-5-nitrophenyl)-4-(pyridine-3-yl) pyrimidine-2-amine is calculated by a main component external standard method with correction factors. The methodology verification shows that the detection method provided by the invention is good in specificity and high in accuracy and sensitivity, and can be used for quality control of related substances in N-(2-methyl-5-nitrophenyl)-4-(pyridine-3-yl) pyrimidine-2-amine, so that the product quality is effectively controlled, and the medication safety of imatinib mesylate is improved.
Owner:SHANDONG LUKANG PHARMA